Review
Biochemistry & Molecular Biology
Karina Maciak, Sylwia Pietrasik, Angela Dziedzic, Justyna Redlicka, Joanna Saluk-Bijak, Michal Bijak, Tomasz Wlodarczyk, Elzbieta Miller
Summary: Multiple sclerosis (MS) and Devic's disease (NMO) are autoimmune, inflammatory diseases of the central nervous system with unclear etiology. Th17 cells and related cytokines may be useful as discriminatory markers for these diseases, but broader immune response mechanisms must also be considered.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Ophthalmology
Andrew R. Carey, J. Fernando Arevalo
Summary: A retrospective chart review of 572 NMOSD patients revealed that 1% of them had uveitis, with bilateral anterior uveitis being the most common subtype. The majority of patients were treated with rituximab for their NMOSD, and in many cases, uveitis attacks preceded demyelination attacks.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Clinical Neurology
Lin Han, Peiwei Hong, Yang Wan, Linjun Cai, Ziyan Shi, Jiancheng Wang, YanLin Lang, Hongyu Zhou
Summary: This study analyzed the employment situation and economic burden of female patients with NMOSD, finding a high unemployment rate. Unemployed patients were usually older, had higher recurrence rates, and more severe disabilities, with lower education levels. Medication and hospitalization costs constituted the main economic burden.
FRONTIERS IN NEUROLOGY
(2022)
Article
Rheumatology
Faria Sami, Shahzad Ahmed Sami, Augustine M. Manadan, Shilpa Arora
Summary: In this study, we investigated the occurrence of NMO in SLE and SS patients and compared the clinical characteristics and outcomes of different groups of NMO hospitalizations. The results showed that NMO patients have a higher risk of SLE and Sjogren's disease, especially in women and certain ethnic groups. These patients have a higher comorbidity index, more complications, longer hospital stays, and higher healthcare costs, but overall mortality rates did not differ significantly.
CLINICAL RHEUMATOLOGY
(2023)
Review
Neurosciences
Mario A. Mireles-Ramirez, Fermin P. Pacheco-Moises, Hector A. Gonzalez-Usigli, Nayeli A. Sanchez-Rosales, Martha R. Hernandez-Preciado, Daniela L. C. Delgado-Lara, Jose J. Hernandez-Cruz, Genaro Gabriel Ortiz
Summary: This article reviews the main pathological findings of NMOSD associated with AQP4 autoantibodies and discusses the mechanisms of astrocyte dysfunction and demyelination. NMOSD is an inflammatory and demyelinating disease mainly affecting the optic nerves and spinal cord. The article emphasizes the importance of detecting AQP4 or other autoantibodies for the correct treatment of the disease.
INTERNATIONAL JOURNAL OF NEUROSCIENCE
(2022)
Article
Neurosciences
Agnieszka Wlodarczyk, Reza Khorooshi, Joanna Marczynska, Inge R. Holtman, Mark Burton, Kirstine Nolling Jensen, Morten Blaabjerg, Morten Meyer, Mads Thomassen, Bart J. L. Eggen, Nasrin Asgari, Trevor Owens
Summary: The study found that IFNI-activated microglia play a pro-pathological role in NMO, while depletion of microglia can suppress pathology and decrease expression of IFNI signature genes, opening up new perspectives for microglia-targeted therapies.
Article
Cell Biology
Priyanka Rajeev Menon, Julia Staab, Anke Gregus, Oliver Wirths, Thomas Meyer
Summary: U-STAT1 affects the signal transduction mediated by P-STAT1 and alters the nucleo-cytoplasmic distribution of P-STAT1. U-STAT1 maintains high levels of cytoplasmic STAT1 by inhibiting the nuclear accumulation of P-STAT1, while preserving IFN γ-induced gene expression.
CELL COMMUNICATION AND SIGNALING
(2022)
Article
Pharmacology & Pharmacy
Chunhua Yuan, Ying Liu, Yankun Hao, Lei Yan, Jun Liang, Huipeng Jin
Summary: The study aimed to compare the efficacy of Rituximab (RTX) and cyclophosphamide (CPM) as maintenance therapy for neuromyelitis optica (NMO). The results showed that RTX was superior to CPM in terms of safety, efficacy, and durability of remission.
Article
Medicine, General & Internal
Dora Nemes-Tomori, Richard Csabalik, Edit Boglarka Nagy, Tibor Beldi, Gyongyike Emese Majai
Summary: This article highlights the rarity of neuromyelitis optica occurring concurrently with two other autoimmune diseases and suggests considering neuromyelitis optica as a differential diagnosis aspect when evaluating patient symptoms.
CLINICAL CASE REPORTS
(2023)
Article
Clinical Neurology
Carolina Monsalve Munoz, Veronica Patino Lopez, Carolina Restrepo-Aristizabal, Maria Isabel Zuluaga Rodas, Natalia Herrera Marin, Sandra Patricia Isaza Jaramillo, Jorge Andres Jimenez Arango
Summary: This study determined the prevalence of Neuro-myelitis Optica Spectrum Disorder (NMOSD) in Antioquia using the Capture-Recapture Method. The prevalence rate in Antioquia was found to be one of the highest reported in the world, except for the French Antilles.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Medicine, General & Internal
Zubir S. Rentiya, Ogbonnaya Akuma, Madiha Haseeb, Chinwe C. Okonkwo, Aadil Khan
Summary: Neuromyelitis optica (NMO) is a central nervous system disorder characterized by optic neuritis and myelitis. MRI and serological examination are crucial for diagnosis, and treatment primarily involves the use of steroids. However, there may be unique cases that deviate from the typical presentation.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Immunology
Gloria Yiu, Tue Kruse Rasmussen, Brandon L. Tsai, Vivian K. Diep, David J. Haddon, Jennifer Tsoi, Gopika D. Miller, Begona Comin-Anduix, Bent Deleuran, Gay M. Crooks, Paul J. Utz
Summary: This study investigates the role of interferon (IFN) signaling in systemic lupus erythematosus (SLE). The results show a correlation between IFN signaling and clinical manifestations as well as immune factors in SLE, suggesting potential targets for future therapeutic approaches.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Sofie Forsberg Soerensen, Martin Wirenfeldt, Agnieszka Wlodarczyk, Marlene Thorsen Moerch, Reza Khorooshi, Dina S. Arengoth, Soeren Thue Lillevang, Trevor Owens, Nasrin Asgari
Summary: The study demonstrated that intrathecal injection of AQP4-IgG+C induced astrocyte pathology in the optic nerve of mice, accompanied by upregulation of gene expression for interferon regulatory factor-7 (IRF7) and CXCL10, highlighting the involvement of type I IFN signaling in the disease process of NMOSD.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Takashi Yamamura, Brian Weinshenker, Michael R. Yeaman, Jerome De Seze, Francesco Patti, Patricia Lobo, H-Christian Von Buedingen, Xiujing Kou, Kristina Weber, Benjamin Greenberg
Summary: This analysis evaluated the long-term safety of satralizumab in patients with NMOSD. The results showed that the safety profile of satralizumab remained consistent in the open-label extension period, with no new safety concerns compared to the double-blind period.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Vinicius Oliveira Boldrini, Mariana Rabelo Brito, Raphael Patricio Silva Quintiliano, Lucas Scardua Silva, Clarissa Lin Yasuda, Fernando Cendes, Alessandro Santos Farias, Alfredo Damasceno
Summary: The expression of serine protease granzyme-B (GzmB) by circulating CD8(+) T lymphocytes may serve as a biomarker for poor immunotherapy response and severe disability in patients with Neuromyelitis Optica spectrum disorders (NMOSD). Venous thromboembolism (VTE) is commonly observed in NMOSD patients with transverse myelitis. This case study highlights the rare occurrence of fatal VTE in an AQP4-positive NMOSD patient with short myelitis (SM) during anti-CD20 treatment.
FRONTIERS IN NEUROLOGY
(2023)
